Evaluating the significance of prenatal diagnosis of cavum septum pellucidum obliteration
Official title: Clinical Significance and Prognostic Value of Prenatal Diagnosis of Obliteration of the Cavum Septum Pellucidum
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06782802 · Data updated 2026-11-12
This study is trying to see if babies diagnosed with a specific brain condition during pregnancy have other problems and how it affects their development after birth.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 28 Days to 44 Years |
| Sex | Women only |
| Enrollment | 15 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, Bologna) |
| Status | Recruiting |
| Started | March 7, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | January 20, 2025 |
| Trial ID | NCT06782802 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pregnant individuals diagnosed with CSP obliteration during second-trimester ultrasounds between 19+0 and 21+6 weeks.
✕Probably not a fit
Patients without a diagnosis of CSP obliteration or those not followed at the participating center may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the incidence of additional abnormalities in fetuses diagnosed with cavum septum pellucidum (CSP) obliteration during second-trimester ultrasounds. It will analyze the postnatal neurological outcomes of these cases, particularly focusing on the relationship between CSP obliteration and associated brain malformations. Patients will be monitored through monthly ultrasounds and follow-up MRIs to detect any further developmental issues. The study will retrospectively review clinical data from patients diagnosed with CSP obliteration at a specific medical center.
Why it matters
Potential benefit: If successful, this study could improve prenatal counseling and management for pregnancies affected by CSP obliteration.
How similar studies have gone: While the approach of using MRI for prenatal diagnosis is established, the specific focus on CSP obliteration and its prognostic implications is less commonly studied, making this a novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant participants with a diagnosis of cavum septum pellucidum obliteration made at second-trimester morphologic ultrasound between 19+0 and 21+6 weeks * Age \> or = 18 years at the time of outpatient access * Acquisition of informed consent form, from the patient and minor * Patients followed at our center Exclusion Criteria: * None
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy Recruiting
Study contacts
- Principal investigator: Gianluigi Pilu, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Gianluigi Pilu, MD
- Email: gianluigi.pilu@aosp.bo.it
- Phone: 0512143493
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aprepitant for CLIFAHDD in young children and adults
This early-phase, safety-focused study tests whether aprepitant can be safely taken daily by people with CLIFAHDD to see if it’s tolerable and may help daily living.
-
SAFE early intervention for high-risk infants to support arm function
This randomized trial tests whether the SAFE early intervention helps improve upper limb function and early development in high-risk infants aged 3–12 months compared with standard Neurodevelopmental Treatment (NDT).
-
TAP-GRIN: L‑serine for GRIN-related neurodevelopmental disorders
This trial will test whether oral L‑serine helps children and young adults (ages 2–30) who have GRIN-related neurodevelopmental disorders caused by loss-of-function variants.
-
Using advanced genome mapping to improve diagnosis of neurodevelopmental disorders
This study is testing a new way to look at genes in children with severe neurodevelopmental disorders to see if it can help find answers when standard tests haven't worked.
-
Long-term follow-up of infants with congenital nevus
Track children under 2 with medium-to-giant congenital nevi to see if they develop neurological problems, melanoma risk, or psychosocial impacts as they grow.
-
Support and characterization of neurodevelopmental disorders in newborns with congenital heart defects
This project will try to see how often and why babies with prenatally diagnosed critical congenital heart defects develop early neurodevelopmental problems by following them from before birth through infancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.